Hemodynamic Response to Intubation

Phase 4

• Conditions: Intubation
• Interventions: Drug: Placebo; Drug: Esmolol; Drug: Dexmedetomidine

• Registration Number: NCT02844894
• Lead Sponsor: Ufuk University

Brief Summary

This study investigates the effects of dexmedetomidine and esmolol given intravenously before intubation on sympathetic response caused by intubation itself. Half the patients will recevice dexmedetomidine and the other half will receive dexmedetomidine. Ischemia modified albumine levels will be measured

Detailed Description

Not available

Study Timeline

• Study Start: 2016-06
• Status Verified: 2016-07
• Study First Submitted: 2016-07-22
• Study First Submitted QC: 2016-07-25
• Last Update Submitted: 2016-07-25
• Study First Posted: 2016-07-26
• Last Update Posted: 2016-07-26
• Primary Completion: 2016-08
• Study Completion: 2016-09

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Patients undergoing elective surgery under general anesthesia

Exclusion Criteria

• Patient refusal
• Morbid obesity (BMI>30)
• Advanced systemic disease
• Hypoalbumiemia
• beta-blocker usage
• Anticipated difficult ventilation and/or intubation

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	20 ml normal saline infused in 5 minutes before intubation
Esmolol	Esmolol	0.5 mg/kg esmolol in 20 ml normal saline will be infused in 5 minutes before intubation
dexmedetomidine	Dexmedetomidine	0.5 mcg/kg dexmedetomidine in 20 ml normal saline will be infused in 5 minutes before intubation

Primary Outcome Measures

Name	Time	Method
ischemia modified albumine	10 minutes after endotracheal intubation	ischemia modified albumine levels will be measured as a response to intubation

Trial Locations

Locations (1)

Ufuk University Hospital; 🇹🇷 Ankara, Turkey